About 20 years ago, investigators working in the National Cancer Institute (NCI) cooperative group system sought to prove that a novel adjuvant therapy regimen would extend the overall survival of patients with stage III colorectal cancer. The CALGB 89803 study compared weekly administration of irinotecan plus fluorouracil and leucovorin vs the standard care at the time, fluorouracil plus leucovorin. Unfortunately, this trial had negative results, and the investigational arm was far more toxic than the standard care.1 The report by Van Blarigan et al2 represents a cancer control gem that came out of the ashes of this trial.
Fisch MJ, McNeill LH, Basen-Engquist KM. Helping Colorectal Cancer Survivors Benefit From Changing Lifestyle Behaviors: Implementation Science and Private Industry Collaboration to the Rescue. JAMA Oncol. 2018;4(6):777–778. doi:10.1001/jamaoncol.2018.0124
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: